Current Therapies and New Strategies for the Management of Alzheimer's Disease

被引:20
作者
Aderinwale, Olapeju G. [1 ]
Ernst, Hans W. [1 ]
Mousa, Shaker A. [1 ,2 ]
机构
[1] Albany Coll Pharm & Hlth Sci, Pharmaceut Res Inst, Rensselaer, NY 12144 USA
[2] King Saud Univ, Riyadh, Saudi Arabia
来源
AMERICAN JOURNAL OF ALZHEIMERS DISEASE AND OTHER DEMENTIAS | 2010年 / 25卷 / 05期
关键词
Alzheimer's disease; beta-amyloid peptide; secretase inhibitors; risk factors; novel therapeutics; MILD COGNITIVE IMPAIRMENT; AMYLOID PRECURSOR PROTEIN; CEREBROSPINAL-FLUID; PERISPINAL ETANERCEPT; LIPID-PEROXIDATION; GAMMA-SECRETASE; BETA-SECRETASE; CSF BIOMARKERS; DOUBLE-BLIND; AD;
D O I
10.1177/1533317510372372
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
030301 [社会学]; 100201 [内科学];
摘要
Alzheimer's disease (AD) is a devastating neurodegenerative disorder that currently affects millions of Americans. There is no cure at present and no real long-term hope for patients with AD. While partially effective in improving symptoms, currently available treatments approved by the US Food and Drug Administration (FDA) do not halt progression of AD, or address the underlying mechanism of the disease, in part because the etiology of AD is still an active area of investigation. Identification of risk factors and the pathogenic mechanism of AD hold the promise of bringing forth novel treatments and perhaps even a cure. In this review, we will summarize some of the risk factors for AD, AD diagnosis, and current treatments. Novel therapeutic strategies such as inhibition of beta-amyloid peptide (A beta), tau-mediated pathogenesis, and receptors for advanced glycation end products (RAGE), as well as neuroprotective and anti-inflammatory approaches and the impact of cholesterol-lowering, botanical, and nutritional agents are also reviewed.
引用
收藏
页码:414 / 424
页数:11
相关论文
共 64 条
[1]
Akuffo EL, 2008, BIOMARKERS, V13, P618, DOI [10.1080/13547500802445199, 10.1080/13547500802445199 ]
[2]
Bales K R, 2002, Mol Interv, V2, P363, DOI 10.1124/mi.2.6.363
[3]
Presenilin clinical mutations can affect γ-secretase activity by different mechanisms [J].
Bentahir, M ;
Nyabi, O ;
Verhamme, J ;
Tolia, A ;
Horré, K ;
Wiltfang, J ;
Esselmann, H ;
De Strooper, B .
JOURNAL OF NEUROCHEMISTRY, 2006, 96 (03) :732-742
[4]
Familial Alzheimer's disease presenilin 1 mutations cause alterations in the conformation of presenilin and interactions with amyloid precursor protein [J].
Berezovska, O ;
Lleo, A ;
Herl, LD ;
Frosch, MP ;
Stern, EA ;
Bacskai, BJ ;
Hyman, BT .
JOURNAL OF NEUROSCIENCE, 2005, 25 (11) :3009-3017
[5]
Cholinesterase inhibitors for Alzheimer's disease [J].
Birks, J .
COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2006, (01)
[6]
Advances in tau-focused drug discovery for Alzheimer's disease and related tauopathies [J].
Brunden, Kurt R. ;
Trojanowski, John Q. ;
Lee, Virginia M. -Y. .
NATURE REVIEWS DRUG DISCOVERY, 2009, 8 (10) :783-793
[7]
Cacabelos R, 1999, INT J GERIATR PSYCH, V14, P3, DOI 10.1002/(SICI)1099-1166(199901)14:1<3::AID-GPS897>3.0.CO
[8]
2-7
[9]
Pyrano[3,2-c]quinoline-6-Chlorotacrine Hybrids as a Novel Family of Acetylcholinesterase- and β-Amyloid-Directed Anti-Alzheimer Compounds [J].
Camps, Pelayo ;
Formosa, Xavier ;
Galdeano, Carles ;
Munoz-Torrero, Diego ;
Ramirez, Lorena ;
Gomez, Elena ;
Isambert, Nicolas ;
Lavilla, Rodolfo ;
Badia, Albert ;
Victoria Clos, M. ;
Bartolini, Manuela ;
Mancini, Francesca ;
Andrisano, Vincenza ;
Arce, Mariana P. ;
Isabel Rodriguez-Franco, M. ;
Huertas, Oscar ;
Dafni, Thomai ;
Javier Luque, F. .
JOURNAL OF MEDICINAL CHEMISTRY, 2009, 52 (17) :5365-5379
[10]
Biomarkers for Alzheimer's disease and other forms of dementia: Clinical needs, limitations and future aspects [J].
Cedazo-Minguez, Angel ;
Winblad, Bengt .
EXPERIMENTAL GERONTOLOGY, 2010, 45 (01) :5-14